Global

With its convergence of healthcare talent and tech, the nation is turning into a prime destination for innovative startups.

A year after the Accelerated Access Review explored how to speed up adoption of innovation across the NHS in England, the UK Government has responded. Leela Barham reports.

While most pharma companies are in partial production using generators, few are operating at 100% capacity, writes Jill Wechsler.

Can health stakeholders be friends without being captives?

European Commission talks drug industry investment, health issues during State of the Union.

Emerging as a bastion of peace, stability, and resilience in a region increasingly beset by political turbulence and economic stagnation, Colombia has been steadily reinventing itself as a Latin American pioneer and pacesetter, including in the world of healthcare.

Leela Barham looks at the reasons behind the Association of the British Pharmaceutical Industry's bid to legally challenge NICE's proposed introduction of the budget impact test.

With our latest review indicating declines in shareholder value and shareholder value to sales, those companies that score well in critical profit management metrics such as return on invested capital are best positioned to maintain that crucial edge in performance execution.

Can the pharma industry truly achieve a patient-centric supply chain? How some clinical trial logistics companies are racing ahead in making the patient a key link in the chain.

Following the unveiling of the UK’s post-Brexit life sciences strategy, Neil Grubert looks at the measures related to market access, a particular challenge in the UK market and key to its future success in the sector.

Reflector asks if the UK's newly announced post-Brexit life sciences strategy report is worth a look as a springboard to addressing future EU ties in healthcare, or just more bluster?

Leela Barham casts her eye over the UK's plans for its life sciences industry in the post-Brexit world.

Dr. Fumie Griego, the International Federation of Pharmaceutical Manufacturers and Associations’ new Assistant Director General, speaks with Pharm Exec about her mission to use IFPMA ’s international reach to find real and practical solutions to the most pressing global healthcare challenges.

With a new consultation from the UK’s Department of Health proposing changes to the Statutory Scheme for Pricing of Branded Medicines, what could this mean for negotiation of a successor to the 2014 Pharmaceutical Price Regulation Scheme (PPRS)? Leela Barham reports.

Indonesia, once considered by global investors as Asia’s “greatest underachiever,” is showing signs of an economic resurgence, nowhere more apparent than in the country’s pharmaceuticals sector.